The present invention relates to an inert carrier Salmonella and potential use thereof, which is expected to be developed into a new inert carrier bacteria, and can be applied to the development of an indirect agglutination test method for simple and rapid detection of antigens or infected antibodies. The inert carrier Salmonella has been deposited in CGMCC in Beijing on Mar. 18, 2019 with the accession number of CGMCC No. 17340, and is classified as Salmonella sp. with a strain code of S9. The Salmonella has no visible agglutination reaction with various chicken sera derived from different genetic backgrounds, i.e., it has no non-specific agglutination reaction with chicken sera derived from broad range of genetic backgrounds.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin.sup.− and/or pagP.sup.−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd.sup.−, purI.sup.− and msbB.sup.−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

Provided is application of genetically engineered bacteria VNP20009-M in preparation of drugs for preventing and treating lung cancer.

Disclosed is a live self-destructing attenuated adjuvant Salmonella strain, or a derivative thereof, capable of safe in ovo inoculation into embryonated avian eggs without reduction in hatchability. In certain examples, the live self-destructing attenuated adjuvant Salmonella strain comprises an attenuated Salmonella typhimurium (S. typhimurium) bacterium, comprising one or more mutations resulting in in vivo self-destruction selected from the group consisting of Δalr, ΔdadB, ΔasdA, ΔP.sub.asdA::TT araC P.sub.araBADasd, ΔP.sub.dadB::TT araC P.sub.araBADdadB, ΔP.sub.asdA::TT rhaRSP.sub.rhaBADasd, ΔP.sub.dadB::TT rhaRSP.sub.rhaBADdadB and/or ΔP.sub.murA::TT rhaRSP.sub.rhaBADmurA. Also disclosed are method of using the attenuated adjuvant Salmonella strains to inoculate Avian species.

Provided herein are methods for identifying and serotyping Salmonella spp. serovars. Primer pairs and nucleic acid probes complementary to signature determinants in specific serovars are utilized for PCR amplification and hybridization for differentiation among specific Salmonella spp. serovars in a single sample.

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with decoy polypeptides that bind endogenous ligand and block activation of signal transduction cascades associated with cancer cell proliferation and tumor growth. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with decoy polypeptides that bind endogenous ligand and block activation of signal transduction cascades associated with cancer cell proliferation and tumor growth. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

The present disclosure relates to Salmonella Gallinarum mutant strains and uses thereof. A vaccine composition according to an aspect has no risk of reverting to pathogenicity, has no residual pathogenicity due to detoxification of an endotoxin, and does not cause lesions and bacterial re-isolation, thereby exhibiting significantly improved safety compared to the existing fowl typhoid vaccines. In addition, since the vaccine composition induces a high-level immune response even when administered to young chicks, it may be used regardless of age, and as the vaccine strain may be used as a live vaccine having an excellent protective capability by itself, the vaccine composition may be useful for preventing and alleviating fowl typhoid.

The present disclosure relates to genetically modified strains of Salmonella, engineered to be tumor navigating, self-eradicating, and armed with TRAIL to trigger tumor cell apoptosis. Also provided herein are methods of producing and methods of using such genetically modified Salmonella strains to treat cancer.

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin.sup.− and/or pagP.sup.−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd.sup.−, purI.sup.−, and msbB.sup.−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.